Decrease in blood miR-296 predicts chemotherapy resistance and poor clinical outcome in patients receiving systemic chemotherapy for metastatic colon cancer.
N
N
Shivapurkar
S
S
Mikhail
R
R
Navarro
W
W
Bai
J
J
Marshall
J
J
Hwang
M
M
Pishvaian
A
A
Wellstein
A R
AR
He
D000069287:Capecitabine; D003110:Colonic Neoplasms / Q000097:blood* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018450:Disease Progression; D019008:Drug Resistance, Neoplasm; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D035683:MicroRNAs / Q000097:blood*; D009362:Neoplasm Metastasis; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib; D016896:Treatment Outcome
D007211:Indoles; C549871:MIRN296 microRNA, human; D035683:MicroRNAs; D011758:Pyrroles; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil; D000077210:Sunitinib